Capricor Therapeutics, Inc. (CAPR) vs Carlsmed, Inc. (CARL)

A side-by-side comparison of Capricor Therapeutics, Inc. and Carlsmed, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CAPR

Capricor Therapeutics, Inc.

$443M

$7.70HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

CARL

Carlsmed, Inc.

$409M

$15.04HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

Total return — CAPR vs CARL

growth of $100 · dividends reinvested · last 1y

CAPR +8.7% (+8.7%/yr)CARL +5.5% (+5.5%/yr)CAPR compounded faster over this window

CAPR CARL

CAPR vs CARL: by the numbers

•CAPR is the larger company ($443M vs $409M market cap).
•Both run net losses; CAPR's is the smaller (0.00% vs -57.42% net margin).

Metrics side by side

Valuation

Metric	CAPR	CARL
P/S ratio	N/A	6.46
P/B ratio	1.80	4.85
EV / EBITDA	0.44	N/A

Profitability

Metric	CAPR	CARL
Gross margin	0.00%	76.63%
Operating margin	0.00%	-61.09%
Net margin	0.00%	-57.42%
ROE	-52.56%	-43.14%
ROIC	-40.25%	-36.54%

Growth (annualized)

Metric	CAPR	CARL
Total return CAGR (5Y)	15.17%	N/A

Go deeper

Full CAPR analysis Full CARL analysis Interactive comparison tool

Dig into the metrics

Capricor Therapeutics ROE Carlsmed ROE Capricor Therapeutics operating margin Carlsmed operating margin Capricor Therapeutics revenue growth Carlsmed revenue growth Capricor Therapeutics free cash flow Carlsmed free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.